Daewoong Pharmaceutical

What Daewoong Pharmaceutical does

Daewoong Pharmaceutical is a Seoul-headquartered, privately held Korean healthcare company founded in 1945 that operates across three converging verticals: branded pharmaceuticals, digital health/hospital AI, and advanced drug delivery/biotech. Its pharmaceutical portfolio spans the PrabotulinumtoxinA botulinum toxin (Nabota) — exported to 17+ Latin American countries and the Middle East — alongside GERD drug Fexuclu, SGLT-2 inhibitor Envlo, idiopathic pulmonary fibrosis candidate Bersiporocin (Phase 2), and a K-Aesthetic Total Solution offering (fillers, PDO threads, training). The technology stack includes proprietary platforms: the CURE drug-delivery platform paired with TionLab's Quject Sphere for monthly semaglutide (reducing injections from 52 to 12 annually), a patented microneedle patch platform for obesity in Phase 1, and the ERA partial cellular reprogramming platform (mRNA-based, acquired from Turn Biotechnologies) targeting ophthalmic and auditory age-related diseases.

Commercially, Daewoong monetizes through export contracts (193 billion won in Nabota exports in 2025; 180 billion won Brazil deal, 29.5 billion won Mexico deal, $24.5 million Colombia deal), licensed technology transfers, and an emerging digital health business that generated 50.9 billion won in 2025 (+123% YoY) on the back of the thynC AI smart-bed monitoring system deployed across 162 Korean hospitals (~15,000 beds, with a stated 100,000-bed target by end-2026) and the "All New THINK" 24-hour health-monitoring platform. Go-to-market combines direct enterprise field sales with regional distribution partnerships (Moksha8 in Latin America, DNC Aesthetics in Indonesia, channel partners across GCC and Southeast Asia), physician education programs (Nabota Master Class, DEEP), and a consumer channel through a 7-Eleven convenience-store health-food partnership. The company is also an active corporate investor via the FreeMind Investments JV (e.g., General Proximity, >$20M raised) and holds a 14.99% stake in spin-off iN Therapeutics, which signed a $500 million Aneratrigine license-out deal with Niroda.

Name

Daewoong Pharmaceutical

Legal name

Daewoong Pharmaceutical Co., Ltd.

Website

https://daewoong.co.kr

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Daewoong Pharmaceutical is a Seoul-based private Korean healthcare company (founded 1945) that develops, manufactures, and globally exports branded pharmaceuticals (Nabota botulinum toxin, Fexuclu, Envlo), AI hospital-monitoring platforms (thynC/THINK), and proprietary drug-delivery and regenerative-medicine platforms targeting obesity and age-related diseases.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Pharmaceutical manufacturing
• Botulinum toxin products
• Digital healthcare platforms
• Drug delivery technology
• Regenerative medicine

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Direct sales of proprietary pharmaceutical products including Nabota botulinum toxin, Fexuclu (GERD drug), Envlo (diabetes drug), and pipeline drugs. Revenue from both domestic Korean market and international exports across multiple regions.
2. Digital Healthcare Solutions: Sales from AI-based healthcare monitoring systems (thynC platform), targeting 100,000 hospital beds with digital healthcare division aiming for 300 billion won annual revenue. Reported 50.9 billion won in digital health sales in 2025.
3. Export Contracts: Major export contracts for Nabota including 180 billion won contract with Brazil, 29.5 billion won contract with Mexico, and 24.5 million USD contract with Colombia's Valentech Pharma.
4. Licensing and Technology Transfer: Revenue from licensing proprietary technologies and platforms to partners, including the acquired ERA platform for age-reversal, microneedle patch platform, and anti-aging technology assets.
5. R&D Investment Returns: Strategic investments through FreeMind Investments (co-founded with FreeMind Group) generating returns from biotech portfolio companies including General Proximity.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels5 records

Core offering

Daewoong Pharmaceutical develops, manufactures, and commercializes branded pharmaceutical products—including the botulinum toxin Nabota, the GERD drug Fexuclu, the SGLT-2 inhibitor Envlo, the IPF therapy Bersiporocin, and the veterinary drug EnvloPet—alongside proprietary AI-based digital health platforms (thynC, THINK) for hospital patient monitoring and advanced drug delivery/regenerative medicine technology platforms (CURE, microneedle patch, ERA). The company sells to hospitals, aesthetic clinics, regional distributors, and consumer channels across Korea, Latin America, the Middle East, and Southeast Asia.

Product overview

Daewoong Pharmaceutical operates as a diversified healthcare company offering both pharmaceutical products and digital health solutions. The pharmaceutical portfolio includes branded drugs (Nabota botulinum toxin, Fexuclu for GERD, Envlo for diabetes, Bersiporocin for IPF) alongside consumer health products and aesthetic treatments (fillers, PDO threads). The digital health division centers on the thynC/THINK AI monitoring platform for hospitals and the CURE platform for drug delivery innovation. The company is expanding into anti-aging therapeutics through the acquired ERA platform and pursuing obesity treatments via multiple delivery technologies including microneedle patches and long-acting injectables.

Differentiator

Problem solved

Functional benefit

Brands

• Nabota: PrabotulinumtoxinA botulinum toxin product for aesthetic and therapeutic applications, exported globally to 17+ Latin American countries and Middle East markets
• Fexuclu
• Envlo
• thynC
• THINK

Products and services

• Nabota (PrabotulinumtoxinA) PrabotulinumtoxinA botulinum toxin product for aesthetic and therapeutic applications, sold to aesthetic clinics, dermatologists, and healthcare providers globally with established presence in 17+ Latin American countries and Middle East markets.
• Fexuclu Gastroesophageal reflux disease (GERD) drug approved in Indonesia and expanding globally across Southeast Asia and other markets for the treatment of GERD.
• Envlo SGLT-2 inhibitor diabetes drug approved in Indonesia for entry into Southeast Asia's largest market, with planned regional expansion to Philippines and Thailand.
• EnvloPet Novel SGLT-2 inhibitor drug for dogs designed to treat diabetes, for which Daewoong has applied for approval in Korea as potentially the world's first SGLT-2 diabetes drug for dogs.
• Bersiporocin Idiopathic pulmonary fibrosis (IPF) drug in Phase 2 clinical trials across South Korea and the U.S., targeting treatment of this progressive fibrotic lung disease.
• thynC AI Smart Bed Monitoring System AI-based smart hospital bed monitoring system that collects biometric data such as heart rate and respiration via wearable devices and sends real-time alerts to medical staff when abnormal signs are detected. Daewoong holds exclusive domestic sales rights in South Korea and the system is deployed at 162 hospitals.
• All New THINK AI Healthcare Platform AI-based healthcare platform providing a nationwide 24-hour health monitoring system aimed at integrating hospitals and homes for continuous patient health management.
• CART ON Ring-Type Blood Pressure Monitor World's first ring-type wearable blood pressure monitoring solution for hospital inpatient wards that integrates with the thynC patient monitoring platform to automatically transmit blood pressure data to nursing station dashboards and hospital EMR systems. Daewoong holds exclusive domestic sales rights in Korea.
• CURE Drug Delivery Platform Daewoong's drug delivery platform combined with TianLab's Quject Sphere technology for developing a long-acting monthly semaglutide injectable for obesity treatment, reducing injection frequency from 52 to 12 times per year.
• Microneedle Patch (Obesity Treatment) Patented microneedle patch platform for obesity treatment that embeds high drug loads in approximately 100 microneedles on a coin-sized patch, with a semaglutide formulation currently in Phase 1 clinical trials.
• ERA Platform (Age-Reversal / Regenerative Medicine) Age-reversal technology platform acquired from Turn Biotechnologies using messenger RNA for partial cellular reprogramming, focused on treating ophthalmic and auditory diseases by inducing aged cells to function like young cells.
• K-Aesthetic Total Solution Platform Comprehensive aesthetic product portfolio launched in Indonesia including the botulinum toxin Nabota, HA and CaHA fillers, and PDO lifting threads, supported by the DEEP physician training program.
• Health Functional Food Products 12 health functional food products launched under the '2-Week Healthy Habit Project' partnership with 7-Eleven, available at over 3,000 convenience stores nationwide in South Korea.

Quantifiable outcome

• 123% increase in digital health sales to 50.9 billion won in 2025
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature8 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Turn BiotechnologiescoreStrategic or Co-development Partner · 26 May 2026Daewoong acquired core assets and technology rights from Turn Biotechnologies including ERA platform for partial cellular reprogramming using messenger RNA. Deal positions Daewoong within regenerative medicine field and allows direct control of underlying IP for age-reversal technology, transitioning from licensee affiliate through HanAll Biopharma.
• TionLab TherapeuticscoreStrategic or Co-development Partner · 8 May 2026Strategic partnership to jointly develop and commercialize long-acting monthly semaglutide injectable for global obesity market. Combines TianLab's Quject Sphere drug delivery technology with Daewoong's CURE platform to reduce injection frequency from 52 to 12 times per year. Filed IND approval in April and planning clinical trials.
• TR (Company)minorChannel Partner/ Reseller/ Distributor · 2 April 2026TR signed supply contract for lung function testers with Daewoong Pharmaceutical, seeking to expand into Vietnam and Japan markets.
• Arc (ARK)coreChannel Partner/ Reseller/ Distributor · 5 March 2026Distribution partnership for AI-based chronic disease complication early screening solutions. Arc secured reservations from over 1,000 hospitals and clinics within one year, with Daewoong supplying products through distribution network nationwide.
• Daewoong TherapeuticscoreStrategic or Co-development Partner · 25 February 2026Exclusive global licensing agreement with R&D affiliate Daewoong Therapeutics to commercialize microneedle patch platform for obesity treatment. Daewoong Pharmaceutical received worldwide commercialization rights to patented technology with semaglutide formulation in Phase 1 trials.
• Seers TechnologycoreTechnology or Integration · 23 February 2026Seers Technology's thynC patient monitoring platform powers Daewoong's AI-based smart hospital bed monitoring system. Partnership enables integration of CART ON ring device and expansion of thynC to 100,000 hospital beds by end of 2026.
• Sky LabscoreChannel Partner/ Reseller/ Distributor · 10 February 2026Daewoong holds exclusive domestic sales rights in South Korea for Sky Labs' CART ON ring-type blood pressure monitor that integrates with Seers Technology's thynC monitoring platform. Product deploys automatically measured BP data to nursing station dashboards and hospital EMR systems.
• M8 (Moksha8) - MexicocoreChannel Partner/ Reseller/ Distributor · 30 January 202629.5 billion won ($20.5 million) export contract for Nabota in Mexico through Moksha8. Entry into fifth top aesthetic market in Latin America following successful Brazil partnership that grew contract volume tenfold over five years.
• Gwangju Health UniversityminorStrategic or Co-development Partner · 30 January 2026Anchor partnership in AI Healthcare Dong-gu Tower project in Gwangju Dong-gu district, transforming area into AI Healthcare Startup and Demonstration Valley with 38 billion won investment over five years.
• Harvard Medical School MGHminorStrategic or Co-development Partner · 30 January 2026Strategic partnership in AI Healthcare Dong-gu Tower project, bringing international academic collaboration to Gwangju AI healthcare ecosystem development.
• OMRON HealthcareminorStrategic or Co-development Partner · 4 November 2025Sky Labs partnership with OMRON Healthcare for global commercialization of CART BP blood pressure monitoring device. Daewoong holds exclusive domestic sales rights in Korea while OMRON expands globally.
• Saudi Arabian PartnersminorStrategic or Co-development Partner · 17 October 2025Discussions with Saudi Arabian officials to explore collaborations in biotechnology and pharmaceuticals, including clinical trials and manufacturing facilities. Saudi biopharma industry projected to grow from $13 billion to $19 billion by 2030.
• Valentech Pharma (Colombia)coreChannel Partner/ Reseller/ Distributor · 26 August 2025$24.5 million export deal with Valentech Pharma to sell Nabota in Colombia. Expands presence in Latin America's fast-growing aesthetics market following similar entries in Brazil, Mexico, and Argentina.
• DNC AestheticscoreChannel Partner/ Reseller/ Distributor · 21 July 2025Joint task force with DNC Aesthetics for K-Aesthetic Total Solution platform launch in Indonesia. Delivers DEEP physician training program for aesthetic procedures including botulinum toxin, fillers, and PDO threads.
• Ark (ARK)coreStrategic or Co-development Partner · 25 April 2025Strategic partnership to expand AI-based fundus imaging platform for early diagnosis of chronic diseases including hypertension, diabetes, and cardiovascular disease. Collaboration integrates Ark's retinal image analysis with Daewoong's drug pipeline for tech-enabled chronic disease care model.
• Chonnam National University HospitalcoreStrategic or Co-development PartnerAI-based smart bed monitoring system thynC deployed at Chonnam National University Hospital and Hwasun Chonnam National University Hospital covering 558 beds - largest deployment among national university hospitals. System serves as model for expanding data-driven patient management nationwide.

Scale indicators17 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• LG Chem Life Sciences: Korean diversified chemical/pharma major with growing branded pharma and biologics franchise. Comparable scale, R&D intensity, and global export strategy targeting LatAm and Southeast Asia.
• Novo Nordisk: Global GLP-1 leader (Ozempic/Wegovy) dominating the obesity market Daewoong targets with long-acting semaglutide and microneedle patch. Establishes the market benchmark and primary competitive threat.
• AbbVie (Allergan Aesthetics): Global leader in botulinum toxin (Botox) and broad aesthetics portfolio. Establishes the competitive ceiling Daewoong's Nabota competes against in LatAm and global markets, and a comparable aesthetic-pharma-plus-platform model.
• Celltrion: Korean biosimilar and specialty pharma giant. Comparable R&D intensity, manufacturing scale, and global commercialization infrastructure — though Celltrion is biosimilar-anchored vs Daewoong's branded/specialty focus.

Direct peers

• Yuhan Corporation: Korean branded pharma with similar size, R&D intensity, and global expansion ambitions. Comparable in product categories (respiratory, gastroenterology, oncology) and competing for Southeast Asia and emerging market share.
• Medytox: Korean botulinum toxin maker (Meditoxin/Innotox) and aesthetic medicine company. Direct competitor to Daewoong in the global toxin market, with overlapping customer base of aesthetic clinics and similar export-focused go-to-market.
• HanAll Biopharma: Korean specialty pharma with historic affiliation to Daewoong through Turn Bio license. Comparable pipeline-focused biotech with immunology, ophthalmology, and rare disease focus.
• Hugel: Korean botulinum toxin and aesthetics specialist competing head-to-head with Daewoong's Nabota in Korea and globally. Both target the same aesthetic clinic segment with toxin products, fillers, and PDO threads. Hugel is the most directly comparable Korean peer.
• Ipsen: French pharma with Dysport/Azzalure botulinum toxin franchise competing directly with Nabota in aesthetics and therapeutics. Comparable diversified specialty pharma with toxin-led global commercial strategy.

Regional players

• Chong Kun Dang (CKD Pharmaceutical): Korean branded pharma with overlapping therapeutic categories (gastroenterology, diabetes) and similar export-driven growth model. Most relevant for direct therapeutic overlap (Envlo vs CKD diabetes portfolio).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daewoong Pharmaceutical